Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

Lukas Vrba, Bernard W. Futscher, Marc Oshiro, George S. Watts, Emmanuel Menashi, Charles Hu, Hytham Hammad, Daniel R. Pennington, Umamaheshwari Golconda, Hemanth Gavini, Denise J. Roe, Rachna T. Shroff, Mark A. Nelson

Research output: Contribution to journalArticlepeer-review

Abstract

We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.

Original languageEnglish (US)
Article number28
JournalClinical Epigenetics
Volume14
Issue number1
DOIs
StatePublished - Dec 2022

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Developmental Biology
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease'. Together they form a unique fingerprint.

Cite this